Back

Carbon emission reduction associated with dapagliflozin compared to standard of care in the UK: translating the DAPA-HF and DELIVER trial findings to an environmental context

31 August 2024 (17:00 - 17:50)
Organised by: Logo
Congress Presentation Part of: Cardiovascular health: from treatment strategies to lifestyle adherence Health Economics ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Luis Horacio Varela Falcon

AstraZeneca, Cambridge (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine according to time of day of vaccination: a post-hoc analysis of the DANFLU-1 randomised clinical trial
Mr J. Christensen (Hellerup, DK)
Abstract Slides Video
Presentation thumbnail
Real world economic evaluation of CT-FFR in patients with suspected coronary artery disease
Doctor J. Peper (Nieuwegein, NL)
Abstract Slides Video
Presentation thumbnail
Type 2 diabetes rather than the presence of significant coronary stenoses is associated with quality of life in angiographied coronary patients
Associate Professor H. Drexel (Feldkirch, AT) Doctor B. Larcher (Feldkirch, AT)
Abstract Slides Video
Presentation thumbnail
Practicing what you preach. Do cardiology trainees in the United Kingdom follow the lifestyle advice that they would give to patients?
Doctor C. Camm (Oxford, GB)
Abstract Slides Video
Presentation thumbnail
Free fatty acids and mortality among adults in the United States: a report from US National Health and Nutrition Examination Survey (NHANES)
Doctor M. Li (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular health: from treatment strategies to lifestyle adherence

The Event

Event poster

ESC Congress 2024

31 August 2024 17:00 CET
You may be interested in
thumbnail
Congress Presentation
A value-based analysis of the systematic use of dapagliflozin in patients with heart failure
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients
thumbnail
Congress Presentation
Dapagliflozin in patients hospitalised with newly diagnosed heart failure: an analysis of the randomized DAPA ACT HF-TIMI 68 trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources